Premium
Immunosuppression reduction in kidney transplant recipients during bacterial infection—A retrospective study
Author(s) -
Yahav Dafna,
Sulimani Omri,
Green Hefziba,
Margalit Ili,
BenZvi Haim,
Mor Eytan,
RozenZvi Benaya
Publication year - 2019
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13707
Subject(s) - medicine , immunosuppression , kidney transplant , retrospective cohort study , kidney transplantation , kidney , immunology , reduction (mathematics) , intensive care medicine , geometry , mathematics
Background Immunosuppression reduction is a common practice in the management of bacterial infection among kidney transplant recipients (KTRs). This practice, however, is based on limited evidence. Methods Retrospective study comparing clinical outcomes of KTRs whose antimetabolite was discontinued vs continued during hospitalization due to bacterial infection, considering calcineurin inhibitors (CNI) levels. Primary outcome was a composite of clinical failure at day 5; all‐cause mortality; and/or re‐hospitalization at 90 days. Multivariable analysis of risk factors for the primary outcome was performed using a propensity‐matched cohort. Results We included 183 KTRs hospitalized with bacterial infection. Neither discontinuation of antimetabolites nor lower levels of CNI at infection onset were associated with a significant decrease the composite primary outcome. No significant difference in graft loss or rejection was demonstrated between patients with low vs high CNI levels or discontinuation vs continuation of antimetabolite. In multivariable analysis, CNI levels and management of antimetabolite were not significantly associated with adverse outcome. Conclusions Immunosuppression reduction in hospitalized KTRs with bacterial infection did not offer a clinical advantage in terms of mortality, re‐hospitalization, or clinical success. An interventional study evaluating continuation of immunosuppression vs reduction should be considered.